Common musculoskeletal disorders in chronic liverdisease patients

Tokgöz, Mehmet Ali; Rampal, Sanjiv; Ranjan, Rajat; Ramayah, Kamarajan; Rajaram, Ruveena; jaiman, ashish; KOONG, JUN KIT

doi:10.52312/jdrs.2021.25

Common musculoskeletal disorders in chronic liverdisease patients

Rajat RANJAN, (Integral University, Integral Institute of Medical Sciences & Research, India)

Sanjiv RAMPAL, (University Putra Malaysia, Faculty of Medicine and Health Sciences, Department of Orthopaedics and Traumatology, Malaysia)

Ashish JAIMAN, (Vardhman Mahavir Medical College & Safdarjung Hospital, Central Institute of Orthopaedics, India)

Mehmet Ali TOKGÖZ, (Ankara Keçiören Training and Research Hospital, Consultant Orthopaedic Surgeon, Ankara, Turkey)

Jun Kit KOONG, (Malaya University, Medical Faculty, Department of Surgery, Malaysia)

Kamarajan RAMAYAH, (University of Malaya Medical Centre, Department of Surgery, Malaysia)

Ruveena RAJARAM (University of Malaya Medical Centre, Department of Medicine, Malaysia)

Joint diseases and related surgery

7 0

Yıl: 2021 Cilt: 32 Sayı: 3 Sayfa Aralığı: 818 - 823 Metin Dili: İngilizce DOI: 10.52312/jdrs.2021.25 İndeks Tarihi: 03-01-2022

Common musculoskeletal disorders in chronic liverdisease patients

Öz:

Chronic liver disease (CLD) is the commonest ailment affectingthe hepatobiliary system. Six significant pathologies related toCLD include hepatic osteodystrophy (HO), increased infectionsusceptibility, sarcopenia, osteonecrosis of the femoral head(OFH), increased risk of periprosthetic complications andfracture. Hepatic osteodystrophy, which comprises osteopenia,osteoporosis, and osteomalacia, refers to alterations in bonemineral metabolism found in patients with CLD. The HOprevalence ranges from 13 to 95%. Low complement levels,poor opsonization capacity, portosystemic shunting, decreasedalbumin levels, and impaired reticuloendothelial system makethe cirrhotic patients more susceptible to developing infectiousdiseases. Septic arthritis, osteomyelitis, prosthetic jointinfection, and cellulitis were common types of CLD-associatedinfectious conditions. The incidence of septic arthritis is1.5 to 2-fold higher in patients with cirrhosis. Sarcopenia, alsoknown as muscle wasting, is one of the frequently overlookedmanifestations of CLD. Sarcopenia has been shown to beindependent predictor of longer mechanical ventilation, hospitalstay, and 12-month mortality of post-transplantation. Alcoholand steroid abuse commonly associated with CLD are thetwo most important contributory factors for non-traumaticosteonecrosis. However, many studies have identified cirrhosisalone to be an independent cause of atraumatic osteonecrosis.The risk of developing OFH in cirrhosis patients increases by2.4 folds and the need for total hip arthroplasty increases by10 folds. Liver disease has been associated with worse outcomesand higher costs after arthroplasty. Cirrhosis is a risk factor forarthroplasty complications and is associated with a prolongedhospital stay, higher costs, readmission rates, and increasedmortality after arthroplasty. Greater physician awareness ofrisk factors associated with musculoskeletal complications ofCLD patients would yield earlier interventions, lower healthcarecosts, and better overall clinical outcomes for this group ofpatients.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Ly KN, Speers S, Klevens RM, Barry V, Vogt TM. Measuring chronic liver disease mortality using an expanded cause of death definition and medical records in Connecticut, 2004. Hepatol Res 2015;45:960-8.
2. Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) 2011;7:661-71.
3. Nakchbandi IA, van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 2009;6:660-70.
4. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014;29:2520-6.
5. Bozkurt HH, Tokgöz MA, Yapar A, Atik OŞ. What is the importance of canal-to-diaphysis ratio on osteoporosisrelated hip fractures? Eklem Hastalik Cerrahisi 2019;30:296-300.
6. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001;33:301-7.
7. George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009;15:3516-22.
8. Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140:180-8.
9. Guañabens N, Cerdá D, Monegal A, Pons F, Caballería L, Peris P, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010;138:2348-56.
10. Tsai CF, Liu CJ, Chen TJ, Chu CJ, Lin HC, Lee Y, et al. Increased incidence of orthopedic fractures in cirrhotic patients: A nationwide population-based study. J Hepatol 2013;58:706-14.
11. Chang CH, Chang CJ, Wang YC, Hu CC, Chang Y, Hsieh PH, et al. Increased incidence, morbidity, and mortality in cirrhotic patients with hip fractures: A nationwide population-based study. J Orthop Surg (Hong Kong) 2020;28:2309499020918032.
12. Savic Z, Damjanov D, Curic N, Kovacev-Zavisic B, Hadnadjev L, Novakovic-Paro J, et al. Vitamin D status, bone metabolism and bone mass in patients with alcoholic liver cirrhosis. Bratisl Lek Listy 2014;115:573-8.
13. Malik P, Gasser RW, Kemmler G, Moncayo R, Finkenstedt G, Kurz M, et al. Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: A cross-sectional study. Alcohol Clin Exp Res 2009;33:375-81.
14. Choudhary NS, Tomar M, Chawla YK, Bhadada SK, Khandelwal N, Dhiman RK, et al. Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci 2011;56:3323-7.
15. Hajiabbasi A, Shafaghi A, Fayazi HS, Shenavar Masooleh I, Hedayati Emami MH, Ghavidel Parsa P, et al. The factors affecting bone density in cirrhosis. Hepat Mon 2015;15:e26871.
16. WangY,WenG,ZhouR,ZhongW,LuS,HuC, et al.Association of nonalcoholic fatty liver disease with osteoporotic fractures: A cross-sectional retrospective study of Chinese individuals. Front Endocrinol (Lausanne) 2018;9:408.
17. Ehnert S, Aspera-Werz RH, Ruoß M, Dooley S, Hengstler JG, Nadalin S, et al. Hepatic osteodystrophy-molecular mechanisms proposed to favor its development. Int J Mol Sci 2019;20:2555.
18. Otete H, Deleuran T, Fleming KM, Card T, Aithal GP, Jepsen P, et al. Hip fracture risk in patients with alcoholic cirrhosis: A population-based study using English and Danish data. J Hepatol 2018;69:697-704.
19. Hamza RE, Villyoth MP, Peter G, Joseph D, Govindaraju C, Tank DC, et al. Risk factors of cellulitis in cirrhosis and antibiotic prophylaxis in preventing recurrence. Ann Gastroenterol 2014;27:374-9.
20. Rocco A, Compare D, Angrisani D, Sanduzzi Zamparelli M, Nardone G. Alcoholic disease: Liver and beyond. World J Gastroenterol 2014;20:14652-9.
21. Malnick SD, Attali M, Israeli E, Gratz R, Geltner D. Spontaneous bacterial arthritis in a cirrhotic patient. J Clin Gastroenterol 1998;27:364-6.
22. Arora A, Rajesh S, Bansal K, Sureka B, Patidar Y, Thapar S, et al. Cirrhosis-related musculoskeletal disease: Radiological review. Br J Radiol 2016;89:20150450.
23. Hung TH, Hsieh MH, Lay CJ, Tsai CC, Tsai CC. Increased occurrence of native septic arthritis in adult cirrhotic patients: A population-based three-year follow-up study in Taiwan. Prz Gastroenterol 2014;9:342-7.
24. Rajesh G, Mehta R, Nandakumar R, Sadasivan S, John A, Balakrishnan V. Skeletal infections in cirrhotics. Indian J Gastroenterol 2005;24:174-5.
25. Kim J, Kang HS, Kim JW, Kim SW, Oh JK, Kim YW, et al. Treatment outcomes in patients with pyogenic vertebral osteomyelitis who have cirrhosis. Sci Rep 2019;9:15223.
26. Lee HJ, Oh MJ. A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease. Clin Mol Hepatol 2013;19:179-84.
27. Sharma P, Tyagi P, Singla V, Bansal N, Kumar A, Arora A. Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis. J Clin Exp Hepatol 2015;5:8-13.
28. Kim JH, Lee JS, Lee SH, Bae WK, Kim NH, Kim KA, et al. Renal dysfunction induced by bacterial infection other than spontaneous bacterial peritonitis in patients with cirrhosis: Incidence and risk factor. Gut Liver 2009;3:292-7.
29. Mohan P, Ramu B, Bhaskar E, Venkataraman J. Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis. Ann Hepatol 2011;10:15-20.
30. Lin MN, Tsai CC, Hung TH, Tsai CC. The risk of cellulitis in cirrhotic patients: A nationwide population-based study in taiwan. Gut Liver 2012;6:482-5.
31. Cheng NC, Tai HC, Tang YB, Chang SC, Wang JT. Necrotising fasciitis: Clinical features in patients with liver cirrhosis. Br J Plast Surg 2005;58:702-7.
32. Huang KF, Hung MH, Lin YS, Lu CL, Liu C, Chen CC, et al. Independent predictors of mortality for necrotizing fasciitis: A retrospective analysis in a single institution. J Trauma 2011;71:467-73.
33. Montano-Loza AJ. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol 2014;20:8061-71.
34. Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 2016;46:951-63.
35. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10:166-73.
36. Kalafateli M, Mantzoukis K, Choi Yau Y, Mohammad AO, Arora S, Rodrigues S, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. J Cachexia Sarcopenia Muscle 2017;8:113-21.
37. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007;46:927-34.
38. Hung TH, Hsieh YH, Tsai CC, Tseng CW, Tseng KC, Tsai CC. Is liver cirrhosis a risk factor for osteonecrosis of the femoral head in adults? A population-based 3-year followup study. Intern Med 2011;50:2563-8.
39. Marvie P, Lisbonne M, L’helgoualc’h A, Rauch M, Turlin B, Preisser L, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010;14:1726-39.
40. Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol 1996;31:500-5.
41. Deleuran T, Overgaard S, Vilstrup H, Jepsen P. Cirrhosis is a risk factor for total hip arthroplasty for avascular necrosis. Acta Orthop 2016;87:231-4.
42. Salomon B, Krause PC, Dasa V, Shi L, Jones D, Chapple AG. The impact of hepatitis C and liver disease on risk of complications after total hip and knee arthroplasty: Analysis of administrative data from Louisiana and Texas. Arthroplast Today 2021;7:200-7.
43. Koenig K, Huddleston JI 3rd, Huddleston H, Maloney WJ, Goodman SB. Advanced age and comorbidity increase the risk for adverse events after revision total hip arthroplasty. J Arthroplasty 2012;27:1402-7.e1.
44. Schairer WW, Vail TP, Bozic KJ. What are the rates and causes of hospital readmission after total knee arthroplasty? Clin Orthop Relat Res 2014;472:181-7.
45. Jiang SL, Schairer WW, Bozic KJ. Increased rates of periprosthetic joint infection in patients with cirrhosis undergoing total joint arthroplasty. Clin Orthop Relat Res 2014;472:2483-91.
46. Onochie E, Kayani B, Dawson-Bowling S, Millington S, Achan P, Hanna S. Total hip arthroplasty in patients with chronic liver disease: A systematic review. SICOT J 2019;5:40.
47. Moon YW, Kim YS, Kwon SY, Kim SY, Lim SJ, Park YS. Perioperative risk of hip arthroplasty in patients with cirrhotic liver disease. J Korean Med Sci 2007;22:223-6.
48. Çağlar Ö, Tokgözoğlu M, Akgün RC, Atilla B. Lowdose vancomycin-loaded cement spacer for two-stage revision of infected total hip arthroplasty. Jt Dis Relat Surg 2020;31:449-55.
49. Kılınç S, Tunç T, Pazarcı Ö, Sümer Z. Research into biocompatibility and cytotoxicity of daptomycin, gentamicin, vancomycin and teicoplanin antibiotics at common doses added to bone cement. Jt Dis Relat Surg 2020;31:328-34.

APA	Ranjan R, Rampal S, jaiman a, Tokgöz M, KOONG J, Ramayah K, Rajaram R (2021). Common musculoskeletal disorders in chronic liverdisease patients. , 818 - 823. 10.52312/jdrs.2021.25
Chicago	Ranjan Rajat,Rampal Sanjiv,jaiman ashish,Tokgöz Mehmet Ali,KOONG JUN KIT,Ramayah Kamarajan,Rajaram Ruveena Common musculoskeletal disorders in chronic liverdisease patients. (2021): 818 - 823. 10.52312/jdrs.2021.25
MLA	Ranjan Rajat,Rampal Sanjiv,jaiman ashish,Tokgöz Mehmet Ali,KOONG JUN KIT,Ramayah Kamarajan,Rajaram Ruveena Common musculoskeletal disorders in chronic liverdisease patients. , 2021, ss.818 - 823. 10.52312/jdrs.2021.25
AMA	Ranjan R,Rampal S,jaiman a,Tokgöz M,KOONG J,Ramayah K,Rajaram R Common musculoskeletal disorders in chronic liverdisease patients. . 2021; 818 - 823. 10.52312/jdrs.2021.25
Vancouver	Ranjan R,Rampal S,jaiman a,Tokgöz M,KOONG J,Ramayah K,Rajaram R Common musculoskeletal disorders in chronic liverdisease patients. . 2021; 818 - 823. 10.52312/jdrs.2021.25
IEEE	Ranjan R,Rampal S,jaiman a,Tokgöz M,KOONG J,Ramayah K,Rajaram R "Common musculoskeletal disorders in chronic liverdisease patients." , ss.818 - 823, 2021. 10.52312/jdrs.2021.25
ISNAD	Ranjan, Rajat vd. "Common musculoskeletal disorders in chronic liverdisease patients". (2021), 818-823. https://doi.org/10.52312/jdrs.2021.25

APA	Ranjan R, Rampal S, jaiman a, Tokgöz M, KOONG J, Ramayah K, Rajaram R (2021). Common musculoskeletal disorders in chronic liverdisease patients. Joint diseases and related surgery, 32(3), 818 - 823. 10.52312/jdrs.2021.25
Chicago	Ranjan Rajat,Rampal Sanjiv,jaiman ashish,Tokgöz Mehmet Ali,KOONG JUN KIT,Ramayah Kamarajan,Rajaram Ruveena Common musculoskeletal disorders in chronic liverdisease patients. Joint diseases and related surgery 32, no.3 (2021): 818 - 823. 10.52312/jdrs.2021.25
MLA	Ranjan Rajat,Rampal Sanjiv,jaiman ashish,Tokgöz Mehmet Ali,KOONG JUN KIT,Ramayah Kamarajan,Rajaram Ruveena Common musculoskeletal disorders in chronic liverdisease patients. Joint diseases and related surgery, vol.32, no.3, 2021, ss.818 - 823. 10.52312/jdrs.2021.25
AMA	Ranjan R,Rampal S,jaiman a,Tokgöz M,KOONG J,Ramayah K,Rajaram R Common musculoskeletal disorders in chronic liverdisease patients. Joint diseases and related surgery. 2021; 32(3): 818 - 823. 10.52312/jdrs.2021.25
Vancouver	Ranjan R,Rampal S,jaiman a,Tokgöz M,KOONG J,Ramayah K,Rajaram R Common musculoskeletal disorders in chronic liverdisease patients. Joint diseases and related surgery. 2021; 32(3): 818 - 823. 10.52312/jdrs.2021.25
IEEE	Ranjan R,Rampal S,jaiman a,Tokgöz M,KOONG J,Ramayah K,Rajaram R "Common musculoskeletal disorders in chronic liverdisease patients." Joint diseases and related surgery, 32, ss.818 - 823, 2021. 10.52312/jdrs.2021.25
ISNAD	Ranjan, Rajat vd. "Common musculoskeletal disorders in chronic liverdisease patients". Joint diseases and related surgery 32/3 (2021), 818-823. https://doi.org/10.52312/jdrs.2021.25